FUNGIZONE POWDER FOR SOLUTION
Country: Kanada
Tungumál: enska
Heimild: Health Canada
Vara einkenni
(SPC)
12-12-2019
Sum skjöl fyrir þessa vöru eru ekki tiltæk eins og er, þú getur sent beiðni til þjónustu við viðskiptavini okkar og við munum láta þig vita um leið og við getum fengið þau.
Senda beiðni.
Senda beiðni.
Virkt innihaldsefni:
AMPHOTERICIN B
Fáanlegur frá:
CHEPLAPHARM ARZNEIMITTEL GMBH
ATC númer:
J02AA01
INN (Alþjóðlegt nafn):
AMPHOTERICIN B
Skammtar:
50MG
Lyfjaform:
POWDER FOR SOLUTION
Samsetning:
AMPHOTERICIN B 50MG
Stjórnsýsluleið:
INTRAVENOUS
Einingar í pakka:
15G/50G
Gerð lyfseðils:
Prescription
Lækningarsvæði:
POLYENES
Vörulýsing:
Active ingredient group (AIG) number: 0105864001; AHFS:
Leyfisstaða:
APPROVED
Leyfisdagur:
2018-06-08
Vara einkenni
MONOGRAPHIE DE PRODUIT
PR
FUNGIZONE
MD
AMPHOTÉRICINE B POUR INJECTION, NORME MANUFACTURER
POUR PERFUSION INTRAVEINEUSE
50 MG/FIOLE
ANTIFONGIQUE
12 décembre 2019
Date de la révision :
N
o
de contrôle : 233219
Tel: 1-888-XEDITON
Ontario L5N 1W1
2000 Argentia Rd, Mississauga,
Xediton Pharmaceuticals Inc,
Distribué par
GmbH
MD
de La Société CHEPLAPHARM Arzneimittel
Ziegelhof 24, 17489 Greifswald, Germany
CHEPLAPHARM Arzneimittel GmbH
CLASSIFICATION THÉRAPEUTIQUE
......................................................................................
3
ACTIONS ET PHARMACOLOGIE
CLINIQUE............................................................................
3
INDICATIONS ET USAGE CLINIQUE
.......................................................................................
3
CONTRE-INDICATION
..............................................................................................................
5
MISES EN GARDE
....................................................................................................................
5
PRÉCAUTIONS
.........................................................................................................................
5
RÉACTIONS INDÉSIRABLES
...................................................................................................
7
SYMPTÔMES ET TRAITEMENT DU SURDOSAGE
................................................................. 9
POSOLOGIE ET ADMINISTRATION
.........................................................................................
9
RENSEIGNEMENTS PHARMACEUTIQUES
............................................................................13
PRÉSENTATION DES FORMES POSOLOGIQUES
................................................................14
MICROBIOLOGIE
.....................................................................................................................14
PHARMACOLOGIE
..................................................................................................................16
TOXICOLOGIE
.........
Lestu allt skjalið
